RESUMEN
BACKGROUND: Both Helicobacter pylori and gastro-oesophageal reflux disease (GORD) may cause inflammation in cardiac mucosa. Intestinal metaplasia (IM) is found more often in GORD associated inflammation than in inflammation caused by H pylori, especially in young individuals. AIM: To examine morphological differences in chronic inflammation in these two conditions by immunohistochemistry. PATIENTS/METHODS: Tissue blocks from cardiac mucosa of patients <45 years were available as follows: 10 patients with chronic inflammation of cardiac mucosa (carditis) and H pylori gastritis (group 1); 10 patients with (possibly GORD related) carditis, but normal antrum and corpus (group 2); and 10 patients with non-inflamed cardiac mucosa and normal antrum and corpus (group 3). Haematoxylin and eosin staining and immunohistochemical staining for various inflammatory cells were performed for patients in groups 1 and 2 as follows: CD20 (B cells), CD3 (T cells), CD4 (T helper cells), CD8 (T suppressor cells), CD163 (macrophages), CD138 (plasma cells), and CD117 (mast cells). For all patients, cytokeratin 7/20 (CK7/20) staining was performed. RESULTS: No clear differences were seen in the morphology of chronic inflammation between groups 1 and 2. In both, plasma cells were most abundant. CK7/20 staining showed no differences between these groups. CONCLUSION: Helicobacter pylori negative (possibly GORD associated) and H pylori related carditis cannot be distinguished on a morphological basis. The stronger tendency towards IM in the first entity cannot be explained by differences in the type of inflammation. Barrett-type CK7/20 staining seems typical for cardiac mucosa, irrespective of the type of inflammation or presence of IM.
Asunto(s)
Reflujo Gastroesofágico/patología , Infecciones por Helicobacter/patología , Helicobacter pylori , Proteínas de Filamentos Intermediarios/análisis , Queratinas/análisis , Miocarditis/patología , Adulto , Antígenos CD/análisis , Biomarcadores/análisis , Enfermedad Crónica , Células del Tejido Conectivo/inmunología , Femenino , Reflujo Gastroesofágico/complicaciones , Infecciones por Helicobacter/complicaciones , Humanos , Queratina-20 , Queratina-7 , Masculino , Membrana Mucosa/química , Membrana Mucosa/patología , Miocarditis/etiología , Células Plasmáticas/inmunología , Linfocitos T/inmunologíaRESUMEN
OBJECTIVE: p27 is a cyclin-dependent kinase inhibitor that prevents progression of the cell cycle from G1 phase. Postranscriptional loss of p27 correlates with poor prognosis in various solid tumors. In pancreatic cancer, the loss of p27 expression has been correlated with high tumor grade and advanced clinical stage, but data on its prognostic value are lacking. METHOD: In this retrospective study, the association between immunohistochemical p27 expression and prognosis was evaluated in 147 patients with pancreatic cancer using a commercial anti-Kip1/p27 monoclonal antibody. RESULT: p27 expression was generally low; in 103 of the 147 pancreatic cancer tumors examined, no nuclear staining was observed and in only 5 specimens did more than 50% of the nuclei stain, probably reflecting the aggressive nature of the disease. Loss of p27 expression was associated with poor prognosis in stage I-II pancreatic adenocarcinoma; the 5-year survival for p27 negative patients was 3.6% compared with 20% for p27-positive patients (p = 0.03). In a multivariate survival analysis in patients with stage I-II disease, p27 (HR 1.8) was a significant prognostic factor, independent of grade (RR 2.9). There was no association between p27 and other clinical variables. In conclusion, tissue expression of p27 is a significant predictor of 5-year survival in stage I-II pancreatic adenocarcinoma.
Asunto(s)
Biomarcadores de Tumor/análisis , Proteínas de Microfilamentos/análisis , Proteínas Musculares , Neoplasias Pancreáticas/química , Anciano , Regulación hacia Abajo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estadificación de Neoplasias , Neoplasias Pancreáticas/patología , Valor Predictivo de las Pruebas , Pronóstico , Análisis de SupervivenciaRESUMEN
The aim of this study was to evaluate the predictive value of intratumoural microvessel density in breast cancer. We studied immunohistochemically primary tumours of 104 patients with metastasised breast cancer who took part in a randomised multicentre trial comparing docetaxel to sequential methotrexate and 5-fluorouracil. Vessels were highlighted with factor VIII staining and counted microscopically. Microvessel density was compared with clinical response to chemotherapy and patient survival. The microvessel density of the primary tumour was not significantly associated with patient's response to chemotherapy, time to progression or overall survival in the whole patient population or in the docetaxel or methotrexate and 5-fluorouracil groups. However, disease-free survival was longer in patients with low microvessel density (P=0.01). These findings suggest that microvessel density of the primary tumour cannot be used as a predictive marker for chemotherapy response in advanced breast cancer.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/irrigación sanguínea , Neoplasias de la Mama/tratamiento farmacológico , Neovascularización Patológica/patología , Paclitaxel/análogos & derivados , Taxoides , Neoplasias de la Mama/mortalidad , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Docetaxel , Femenino , Fluorouracilo/administración & dosificación , Humanos , Metotrexato/administración & dosificación , Paclitaxel/administración & dosificación , Pronóstico , Factores de Tiempo , Resultado del TratamientoRESUMEN
Breast cancer patients with c-erbB-2-positive tumours seem to benefit from anthracycline-based adjuvant chemotherapy. The predictive value of c-erbB-2 for taxane sensitivity is not yet clear. The purpose of this study was to assess whether c-erbB-2 expression is associated with clinical sensitivity to docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). A total of 283 patients with metastatic breast cancer were initially enrolled in a randomised multicentre trial comparing docetaxel with sequential MF in advanced breast cancer. Paraffin-embedded blocks of the primary tumour were available for 131 patients (46%). c-erbB-2 status was determined by immunohistochemistry using a polyclonal antibody to the c-erbB-2 protein. C-erbB-2 expression was scored in a semi-quantitative fashion using a 0 to 3+ scale. Staining scores 2+ or greater were considered positive. Response evaluation was performed according to World Health Organization (WHO) recommendations. Overall 54 (42%) patients had c-erbB-2-positive tumours. There was no association between treatment outcome and c-erbB-2 overexpression. The overall response rates (RR) (n=128) among c-erbB-2-negative and -positive patients were 35 and 44%, respectively (P=0.359). In the MF arm (n=62), the RR was somewhat higher in the c-erbB-2 overexpressors (33% versus 18%, P=0.18). In the docetaxel arm the RRs were very similar, regardless of the c-erbB-2 expression (53% versus 53%). While several studies have suggested a prognostic and putative predictive significance of c-erbB-2 overexpression in early breast cancer, the significance of c-erbB-2 expression as a predictive factor for response to various cytotoxic treatments in advanced breast cancer is still controversial. In this study, c-erbB-2 expression could not predict response to either MF or T. Thus, tumours over-expressing c-erbB-2 are not uniformly more sensitive to taxanes and c-erbB-2 expression cannot yet be applied clinically as a predictive factor for response in advanced breast cancer.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Proteínas de Neoplasias/efectos de los fármacos , Paclitaxel/análogos & derivados , Paclitaxel/uso terapéutico , Receptor ErbB-2/efectos de los fármacos , Taxoides , Adolescente , Adulto , Anciano , Neoplasias de la Mama/metabolismo , Quimioterapia Adyuvante , Docetaxel , Femenino , Fluorouracilo/administración & dosificación , Humanos , Metotrexato/administración & dosificación , Persona de Mediana Edad , Proteínas de Neoplasias/metabolismo , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Receptor ErbB-2/metabolismoRESUMEN
Sialyl-Tn (STn) is a carbohydrate antigen formed by the premature 2-6 sialylation of N-acetylgalactosamine. It belongs to a family of antigens widely expressed in carcinomas but only to a limited degree in normal tissue. The expression of STn has been associated with prognosis in different tumors. In this immunohistochemical study of 218 patients with invasive stage I-III breast cancer, STn was expressed in 39% of the tumors. High expression of STn correlated with estrogen and progesterone hormone receptor negativity (p = 0.0002 and p = 0.0003, respectively), and marginally with large tumor size (p = 0.04), high S-phase fraction (p = 0.04) and aneuploidy (p = 0.04), but not significantly with node status, grade or age. The patients had a median follow-up of 17 years. The breast-cancer-specific survival rate of patients with STn-negative cancers was higher than that of patients with cancers that expressed STn during the first 5 years of the follow-up (p = 0.013), but the difference between the groups decreased during the long-term follow-up. STn expression seems to be a marker for short-term, but not for long-term breast cancer outcome prediction.
Asunto(s)
Antígenos de Carbohidratos Asociados a Tumores/análisis , Biomarcadores de Tumor/análisis , Neoplasias de la Mama/patología , Aneuploidia , Neoplasias de la Mama/mortalidad , Femenino , Humanos , Inmunohistoquímica , Metástasis Linfática , Invasividad Neoplásica , Estadificación de Neoplasias , Ploidias , Pronóstico , Receptores de Estrógenos/análisis , Receptores de Progesterona/análisis , Estudios Retrospectivos , Fase S , Tasa de Supervivencia , Factores de TiempoRESUMEN
UNLABELLED: New prognostic and predictive factors are needed to adjust more appropriate therapy for individual patients after operation. p27 is a cell cycle regulator, and a low tissue expression of this protein has been shown to correlate with poor prognosis in colorectal, lung, gastric, prostate, and breast cancer. In this study on 197 breast cancer patients with a median follow-up of 17 years, the prognostic value of immunohistochemical p27 expression was evaluated. After 5 years of follow-up patients with a p27 expression in less than 50% of the tumor cells had a significantly lower survival rate than those with an expression above this level (p = 0.01). However, after longer follow-up the difference decreased and was no longer significant at 7 years (p = 0.1) or when the entire follow-up period was examined (p=0.67). Tests for associations showed that a low p27 expression correlated with a high histologic grade, a high S-phase fraction (SPF), an advanced TNM stage and negative hormone receptor status. IN CONCLUSION: Tissue expression of p27 is a significant predictor of 5-year, but not of 10- or 15-year breast cancer specific survival.
Asunto(s)
Neoplasias de la Mama/mortalidad , Proteínas de Microfilamentos/metabolismo , Proteínas Musculares , Proteínas de Neoplasias/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Neoplasias de la Mama/metabolismo , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Femenino , Humanos , Persona de Mediana Edad , PronósticoRESUMEN
AIMS: Human chorionic gonadotropin (hCG) beta in serum is a promising tumour marker for gastrointestinal malignancies. Our aim was to investigate the expression of hCGbeta by immunohistochemistry in various gastrointestinal cancers and benign tissues. METHODS AND RESULTS: A monoclonal antibody (MAb) specific for free hCGbeta was used to stain 107 tissue samples from various gastrointestinal malignancies and 36 benign or normal tissue samples. The specificity of the staining was verified and the results compared with those obtained with a widely used commercial polyclonal antibody (PAb) which reacts with both free hCGbeta and intact hCG, as well as with luteinizing hormone beta. With the MAb, we observed positive immunohistochemical staining in 24% of the malignant gastrointestinal tumours. Gastric (60%) and pancreatic (56%) carcinomas, as well as extrahepatic cholangiocarcinomas (36%), were positive most frequently. We also discovered immunoreactivity in half of the non-malignant samples from pancreatic and biliary tissues. With the PAb, hCG immunoreactivity was evident more frequently in some cancers, but the staining was diffuse and occasionally polymorphonuclear leucocytes were strongly stained. CONCLUSIONS: This study shows that our MAbs specific for hCGbeta are well suited for immunohistochemistry. Our results confirm previous findings on gastrointestinal cancers and, furthermore, we demonstrate hCGbeta tissue expression in pancreatic adenocarcinoma. The results support reports on hCGbeta as a serum tumour marker for digestive tract diseases.
Asunto(s)
Gonadotropina Coriónica Humana de Subunidad beta/análisis , Sistema Digestivo/patología , Neoplasias Gastrointestinales/patología , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Anticuerpos Monoclonales/inmunología , Gonadotropina Coriónica Humana de Subunidad beta/inmunología , Sistema Digestivo/química , Neoplasias Gastrointestinales/metabolismo , Humanos , InmunohistoquímicaRESUMEN
The prognostic value of the immunohistochemical expression of epithelial and stromal syndecan-1 was evaluated in 296 patients with gastric carcinoma. Formalin-fixed, paraffin-embedded specimens of gastric adenocarcinomas were stained with mouse monoclonal antibody B-B4 against human syndecan-1. Loss of immunoreactivity (syndecan-1 immunoreactivity correlated with a higher stage of disease (stages II-IV), tumour location in the upper third of the stomach, nodal metastases (N1 or N2), positive stromal syndecan-1 staining, deep tumour penetration (to subserosa or deeper = T2-T4), larger tumour size (> or = 5 cm) and intestinal type of cancer. No correlation between epithelial syndecan-1 immunoreactivity and age, gender, distant metastases, grade of differentiation or Borrmann classification was observed. Positive stromal syndecan-1 immunoreactivity correlated with decreased epithelial syndecan-1 expression, intestinal type of cancer and Borrmann type I. Patients with low epithelial syndecan-1 expression in cancer cells had worse overall survival than patients with strong epithelial syndecan-1 staining (p = 0.0012). Stromal syndecan-1-positive patients had a worse outcome than patients with syndecan-1-negative stroma (p = 0.0193). In Cox multivariate analysis, stromal syndecan-1 immunoreactivity was a prognostic factor independent of TNM stage, surgery for cure and tumour size. Thus, the immunohistochemical expression of syndecan-1 might be a predictor of outcome in patients with gastric adenocarcinoma.
Asunto(s)
Epitelio/metabolismo , Glicoproteínas de Membrana/biosíntesis , Proteoglicanos/biosíntesis , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/terapia , Células del Estroma/metabolismo , Adenocarcinoma/diagnóstico , Adenocarcinoma/metabolismo , Adenocarcinoma/mortalidad , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Animales , Anticuerpos Monoclonales/metabolismo , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Metástasis Linfática , Masculino , Ratones , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Factores Sexuales , Neoplasias Gástricas/mortalidad , Sindecano-1 , Sindecanos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Tumor-associated trypsin inhibitor (TATI) is a 6-kDa peptide, which is identical to the pancreatic-secretory-trypsin inhibitor (PSTI). TATI is produced by several tumors and cancer cell lines, and is used as a serum marker for mucinous ovarian cancer. Elevated serum levels of TATI have also been observed in renal-cell carcinoma (RCC). However, it is unclear whether the increase of serum TATI in this disease is caused by production of TATI by the tumor tissue, by the acute-phase reaction frequently associated with cancer, or by impaired renal function. We examined the expression of TATI in malignant and histologically normal renal tissue by immunohistochemistry, in situ hybridization and reverse-transcriptase-polymerase-chain reaction (RT-PCR). Furthermore, we measured pre-operative serum TATI levels in 21 patients with RCC. Immunohistochemically, TATI was detected in 13 of 20 histologically normal renal-tissue samples, but not in 32 tissue samples from RCC. By RT-PCR, TATI mRNA was detected in all of 10 histologically normal kidneys and in 6 of 11 RCCs, while in situ hybridization analysis gave negative results. Pre-operative serum TATI was elevated in 57% of RCC patients. We also studied expression of TATI mRNA and protein in 7 renal-cancer cell lines, by RT-PCR and immunofluorometric assay respectively: 6 cancer cell lines were positive for TATI mRNA, while 4 of them also produced TATI protein at low levels. These results indicate that TATI is synthesized by the histologically normal renal tissue and by some renal cancers, and suggest that the elevation of serum TATI associated with renal-cell carcinoma may be caused by the release of TATI produced by the tumor.
Asunto(s)
Carcinoma de Células Renales/metabolismo , Neoplasias Renales/metabolismo , Riñón/metabolismo , Inhibidor de Tripsina Pancreática de Kazal/biosíntesis , Inhibidor de Tripsina Pancreática de Kazal/sangre , Carcinoma de Células Renales/sangre , Humanos , Inmunohistoquímica , Neoplasias Renales/sangre , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidor de Tripsina Pancreática de Kazal/genética , Células Tumorales CultivadasRESUMEN
RATIONALE AND OBJECTIVES: Angiogenesis and proliferation activity are important indicators of tumor behavior in human gliomas. The authors studied how tumor enhancement in MR imaging and intratumoral vascular density were correlated with cell proliferation in cerebral gliomas. METHODS: The authors studied retrospectively 62 cerebral gliomas. Patients were examined before surgery with contrast-enhanced MR imaging. Microvessel density and the cell proliferation rate of tumor specimens were measured immunohistochemically using factor VIII and MIB-1 antibodies. Contrast enhancement of the tumors was evaluated by two radiologists. RESULTS: Contrast enhancement was observed in 45 tumors and was correlated with histologic cell proliferation (P = 0.0007) and microvessel density (P = 0.01). There was also a correlation between tumor vascular density and the cell proliferation rate (r = 0.51, P < 0.0001). Histologic tumor grade was associated with vascular density (P = 0.001). CONCLUSIONS: Lesion enhancement on preoperative contrast-enhanced MR imaging correlates with vascularity and proliferation activity of gliomas. The additional correlation between tumor vascularity and proliferation suggests that intratumoral microvessel density could be useful in estimating tumor proliferation.
Asunto(s)
Glioma/irrigación sanguínea , Glioma/patología , Imagen por Resonancia Magnética , Neoplasias Supratentoriales/irrigación sanguínea , Neoplasias Supratentoriales/patología , Adulto , Encéfalo/irrigación sanguínea , Encéfalo/patología , División Celular , Femenino , Humanos , Masculino , Neovascularización Patológica/patología , Estudios RetrospectivosRESUMEN
We measured microvessel density and cell proliferation index in 84 breast cancers using survival analysis to find out their prognostic value. Immunohistochemistry was applied using antibody to factor VIII-related antigen as a marker for microvessels and MIB-1 antibody to stain proliferating cells. We were not able to show any difference in survival with a mean follow-up of 10.3 years between patients with high and low microvessel count or cell proliferation index. Vascular density did not correlate with the cell proliferation rate (p = 0.4). However, patient age correlated negatively with the cell proliferation index of the tumor (p = 0.0009). There was no significant difference both in microvessel count and in cell proliferation between patients with lymph node metastasis and node negative patients. This result questions the usefulness of vascular density and cell proliferation rate as prognostic markers in breast cancer.
Asunto(s)
Adenocarcinoma/irrigación sanguínea , Adenocarcinoma/patología , Neoplasias de la Mama/irrigación sanguínea , Neoplasias de la Mama/patología , Neovascularización Patológica/patología , Adenocarcinoma/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/mortalidad , Carcinoma Ductal de Mama/irrigación sanguínea , Carcinoma Ductal de Mama/mortalidad , Carcinoma Ductal de Mama/patología , Carcinoma Lobular/irrigación sanguínea , Carcinoma Lobular/mortalidad , Carcinoma Lobular/patología , División Celular , Femenino , Estudios de Seguimiento , Humanos , Técnicas para Inmunoenzimas , Antígeno Ki-67/análisis , Persona de Mediana Edad , Pronóstico , Tasa de Supervivencia , Factor de von Willebrand/análisisRESUMEN
We have recently demonstrated an association between distant metastasis and the expression of the extracellular matrix glycoprotein tenascin-C (Tn-C) in the invasion border of small axillary node-negative breast carcinomas. Our purpose was to assess the relationship between the expression of Tn-C in the tumour invasion border and several histopathological and biological variables and to compare their usefulness in predicting local and distant disease recurrences. The original patient group consisted of 143 women with axillary node-negative breast cancer (one bilateral) treated with breast-conserving surgery and post-operative radiotherapy, and followed for a median of 8 years. Because of the small number of recurrences an additional group of 15 similarly treated women with recurrent breast cancer was also studied. The size of the tumour, its histology, including a possible intraductal component, and grade were re-evaluated. The expression of erbB-2, p53, Ki-67 and Tn-C was evaluated by immunohistochemistry. Ploidy and S-phase fraction (SPF) were assessed by flow cytometry. The only statistically significant prognostic factor for local recurrence was Tn-C expression in the invasion border. For metastasis Ki-67 positivity, tumour size and Tn-C expression in the invasion border were statistically significant, but Ki-67 positivity was the only independent prognostic factor. Tn-C expression in the invasion border was associated with a higher proliferation rate measured by Ki-67 and SPF, which is consistent with the suggested growth-promoting activity of Tn-C. Tn-C may be a useful marker in selecting patients for adjuvant therapies to reduce the rate of both local and distant cancer recurrences.
Asunto(s)
Neoplasias de la Mama/metabolismo , Proteínas de Neoplasias/metabolismo , Tenascina/metabolismo , Adulto , Anciano , Análisis de Varianza , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Antígeno Ki-67/metabolismo , Persona de Mediana Edad , Invasividad Neoplásica , Recurrencia Local de Neoplasia/metabolismo , Ploidias , Fase SRESUMEN
Infantile onset spinocerebellar ataxia (IOSCA, MIM 271245) is a recessively inherited, progressive neurological disease, which we have described in 19 Finnish patients. The clinical symptoms of IOSCA include ataxia, athetosis, hypotonia, hearing deficit, ophthalmoplegia, sensory neuropathy, female hypogonadism, and epilepsy as a late manifestation. We have mapped the IOSCA locus to 10q24. In our two autopsy cases of IOSCA, the neuropathological findings were almost uniform. The cerebral hemispheres were quite well preserved, but the brain stem and the cerebellum were moderately atrophic. The most severe atrophic changes were seen in the spinal cord: in the dorsal roots, the posterior columns and the posterior spinocerebellar tracts. There was a severe neuronal loss in the dorsal nucleus (Clarke's column) of both cases and slight atrophy of the intermediolateral column in one case. The cerebellar peduncles, the inferior olives, the accessory cuneate nuclei and especially the dentate nuclei were atrophic and gliotic. The eighth cranial nerve and nucleus were atrophic. The ventral pontine nuclei and transverse fibers were slightly affected. Tegmental nuclei and tracts, especially sensory structures, were more severely affected. In mesencephalon, there was atrophy of the oculomotor nuclear complex and periaqueductal gray matter. The cerebellar cortex showed patchy atrophy. Degenerative changes were seen in dorsal root ganglia, and there was a severe axonal loss in the sural nerve. The neuropathological picture of IOSCA thus seems close to that reported in Friedreich's ataxia, another recessively inherited usually childhood-onset ataxia.
Asunto(s)
Edad de Inicio , Neuropatías Hereditarias Sensoriales y Autónomas/patología , Degeneraciones Espinocerebelosas/epidemiología , Degeneraciones Espinocerebelosas/patología , Encéfalo/patología , Femenino , Humanos , Inmunohistoquímica , Lactante , Masculino , Microscopía Electrónica , Músculos/patología , Nervios Periféricos/patología , Médula Espinal/patologíaRESUMEN
To evaluate the spatial and temporal expression of type V collagen in a wound healing model, subcutaneously implanted viscose cellulose sponges in rats were used to induce granulation tissue formation. Analyses on granulation tissue were carried out on days 3, 5, 8, 14, 21, 30, 59 and 84. Acid soluble collagens were extracted and the relative amount of type V collagen was quantified by SDS-PAGE. Specific antibodies to type I, III and V collagens were used in immunohistochemistry and specific RNA probes to proalpha1(I), proalpha1(III) and proalpha1(V) collagen in in situ hybridization. Type V collagen content increased relative to type I and III collagens up to day 8 and remained at the same level for up to the three months. Type V collagen was expressed strongly in blood vessel walls as seen in immunohistochemistry. In situ hybridization showed that all of the three types of collagen were expressed mostly in fibroblast-like cells and also in rounded cells, especially type V collagen. In conclusion, type V collagen was seen in the wound healing model in increasing amounts from day 3 onwards, its localization being highly associated with blood vessels in granulation tissue and it was synthesized by fibroblast-like and rounded cells.